Cost-effectiveness of the SQ HDM SLIT-tablet for the treatment of allergic asthma in three Eastern European CountriesW. Green1william.firstname.lastname@example.orgK, J. McMaster1, R. Babela*2,3, S. Buchs3Show more: Authors information and Publication history
York Health Economics Consortium, Enterprise House, Innovation Way, University of York, Heslington, York, UK2
St. Elisabeth University, Institute of Healthcare Disciplines, Bratislava, Slovakia 3
ALK-Abelló, Denmark *
RB was an employee of ALK-Abelló at the time when this research was conducted.
Published online: 12 November 2018
Accepted: 10 October 2018
Received:20 July 2018
https://doi.org/10.23822/EurAnnACI.1764-1489.78 Summary Background.
The standardized quality (SQ®) house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet (acarizax®, ALK-Abelló A/S, Hørsholm, Denmark) is an allergy immunotherapy tablet for people with allergic respiratory disease. This analysis aims to assess the cost-effectiveness of the SQ HDM SLIT-tablet from the perspective of three Eastern European countries: Czech Republic, Poland and Slovakia. Methods.
A cost-utility model per country was developed, which compared the SQ HDM SLIT-tablet as add-on to pharmacotherapy with pharmacotherapy alone in patients with HDM allergic asthma (AA) over a five year time horizon. The effectiveness of the two interventions was based on the results from a large-scale randomised controlled trial. In the models, annual costs and quality-adjusted life year (QALY) scores from the trial were extrapolated over a five year period, and the incremental cost-effectiveness ratios (ICERs) were estimated. One-way deterministic sensitivity and scenario analyses were undertaken. Results.
The SQ HDM SLIT-tablet is cost-effective in all three markets over the five year time horizon (ICERs of less than € 10,000 per additional QALY). Treatment with the SQ HDM SLIT-tablet improves patient outcomes, with QALY gains of 0.35, versus pharmacotherapy only. In all three countries, the SQ HDM SLIT-tablet also incurs increased costs compared to pharmacotherapy treatment only. The sensitivity analysis identified utility values from the clinical trial as the main driver of the model results. Conclusion.
The SQ HDM SLIT-tablet is a cost-effective treatment option for people with HDM AA in three different health care settings in Eastern Europe.Key words
cost-effectiveness; allergic asthma; allergy immunotherapy; sublingual immunotherapy; SQ HDM SLIT-tablet
Cite this article as:
Green W, McMaster J, Babela R, Buchs S. Cost-effectiveness of the SQ HDM SLIT-tablet for the treatment of allergic asthma in three Eastern European Countries ;Eur Ann Allergy Clin Immunol. 2019;51(1):68-74. doi:10.23822/EurAnnACI.1764-1489.78